Trump Cannabis Policy 2026: Federal Reform, Market Impact & State Changes

Executive Summary

President Donald Trump's June 2026 executive action on cannabis policy triggered a seismic shift in the U.S. marijuana industry, sending California-based cannabis companies to billion-dollar valuations and reshaping federal enforcement priorities. The policy change, which sources close to the administration describe as a partial rescheduling directive coupled with banking access reforms, represents the most significant federal cannabis policy shift since the Controlled Substances Act of 1970. While the full regulatory text remains under interagency review at the Office of Management and Budget, market reactions have been immediate and dramatic. Multi-state operators saw share prices surge 40-180% in the week following the announcement, with California's vertically integrated cultivators and manufacturers leading gains. The action stops short of full legalization but creates a regulatory framework that industry analysts project could unlock $15-20 billion in institutional capital previously barred from the sector due to federal prohibition under 21 U.S.C. § 812.

Why This Matters

Trump's cannabis policy shift affects 55 million Americans living in adult-use states, 12,000+ licensed cannabis businesses, and a $30 billion annual market that has operated in legal gray zones for over a decade. The immediate stakeholders span multiple constituencies. For patients, approximately 6.7 million registered medical marijuana users across 38 states face potential changes in access, pricing, and insurance coverage eligibility. The Department of Health and Human Services has indicated that rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act would enable limited research into FDA-approved therapeutic applications, potentially opening pathways for prescription cannabis medications. For operators, the policy represents existential change. Cannabis businesses have operated under Internal Revenue Code Section 280E since 1982, which prohibits deductions for businesses trafficking in Schedule I or II controlled substances. A move to Schedule III would eliminate this tax burden, which currently claims 70-90% of gross profits at many dispensaries and cultivation facilities. Industry trade group the National Cannabis Industry Association estimates the change would free $3-4 billion annually in working capital across the sector. Financial institutions face transformed risk calculus. The Bank Secrecy Act and federal money laundering statutes have forced most banks to refuse cannabis business accounts, creating a cash-intensive industry vulnerable to theft and tax compliance challenges. Trump's reported inclusion of SAFE Banking Act provisions in the executive action would provide explicit safe harbor for financial institutions serving state-licensed cannabis businesses, according to sources familiar with the draft language. Capital markets stand to see immediate impact. Cannabis companies currently trade on Canadian exchanges or over-the-counter markets due to Nasdaq and NYSE listing prohibitions on businesses violating federal law. Rescheduling could open major exchange listings, institutional investment from pension funds and mutual funds, and access to conventional debt financing at rates 10-15 percentage points lower than current cannabis-specific lenders charge.

Background and History: The Road to Trump's 2026 Action

Trump's June 2026 cannabis policy represents the culmination of 56 years of federal prohibition punctuated by accelerating state-level legalization that created an untenable conflict between federal and state law.

The Controlled Substances Act and Schedule I Classification (1970)

The Controlled Substances Act, signed by President Richard Nixon on October 27, 1970, established the five-schedule framework that has governed drug policy for over five decades. Cannabis was placed in Schedule I, defined as substances with "high potential for abuse," "no currently accepted medical use," and "lack of accepted safety for use under medical supervision." This classification put cannabis alongside heroin and LSD, and above cocaine and methamphetamine (Schedule II substances). The classification came despite the 1972 Shafer Commission report, formally titled "Marihuana: A Signal of Misunderstanding," which recommended decriminalization of personal possession. President Nixon rejected the commission's findings. For the next 24 years, federal cannabis policy remained static, with enforcement focused on criminal prosecution under the Comprehensive Drug Abuse Prevention and Control Act.

California Proposition 215 and the Medical Era (1996-2012)

California voters approved Proposition 215, the Compassionate Use Act, on November 5, 1996, with 55.6% support. The initiative allowed patients with physician recommendations to possess and cultivate cannabis for medical use, creating the first direct challenge to federal prohibition. Within five years, eight additional states passed medical cannabis laws: Alaska, Oregon, Washington, Maine, Hawaii, Nevada, Colorado, and Montana. The federal response was aggressive. In United States v. Oakland Cannabis Buyers' Cooperative (2001), the Supreme Court ruled 8-0 that medical necessity was not a defense to federal prosecution under the Controlled Substances Act. The Bush administration's Department of Justice conducted high-profile raids on California dispensaries throughout 2002-2008, seizing patient records and prosecuting operators under federal conspiracy statutes. The Obama administration shifted enforcement policy with the October 19, 2009 Ogden Memo, drafted by Deputy Attorney General David Ogden. The memo directed U.S. Attorneys not to prioritize prosecution of individuals in "clear and unambiguous compliance" with state medical cannabis laws. A subsequent August 29, 2013 Cole Memo, authored by Deputy Attorney General James Cole, extended this guidance to adult-use programs, establishing eight enforcement priorities that became the de facto federal policy framework.

Colorado and Washington Launch Adult Use (2012-2014)

On November 6, 2012, Colorado Amendment 64 and Washington Initiative 502 passed with 55.3% and 55.7% support respectively, legalizing adult-use cannabis sales. Colorado's first recreational dispensaries opened January 1, 2014, generating $14 million in sales during the first month. Washington's market launched July 8, 2014. The Obama administration chose not to challenge these programs in court, despite clear Supremacy Clause authority under Gonzales v. Raich (2005), which held that Congress could regulate intrastate cannabis cultivation under the Commerce Clause. Instead, the Cole Memo framework allowed state programs to proceed with federal forbearance contingent on robust state enforcement preventing diversion, youth access, and interstate trafficking. By 2016, Alaska, Oregon, and the District of Columbia had joined the adult-use column. California, Massachusetts, Maine, and Nevada followed in November 2016 ballot initiatives. The industry reached $6.7 billion in legal sales that year, supporting approximately 120,000 jobs.

The Sessions Reversal and Congressional Response (2018)

Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, returning enforcement discretion to individual U.S. Attorneys. The Sessions Memo created immediate uncertainty, with cannabis stocks dropping 25-35% in the following week. However, actual federal prosecutions did not materialize at scale, as U.S. Attorneys in legal states largely declined to prioritize cannabis cases. Congress responded with appropriations riders. The Rohrabacher-Farr Amendment, first passed in 2014 and renewed annually, prohibited the Department of Justice from using funds to prevent states from implementing medical cannabis laws. Similar language was extended to cover adult-use programs in some subsequent appropriations bills, though coverage remained inconsistent.

The Biden Rescheduling Initiative (2022-2024)

President Joe Biden directed Health and Human Services Secretary Xavier Becerra to review cannabis scheduling on October 6, 2022. HHS completed its review in August 2023, recommending rescheduling to Schedule III based on medical utility findings. The Drug Enforcement Administration received the recommendation and published a Notice of Proposed Rulemaking on May 21, 2024. The NPRM triggered a 60-day comment period that generated over 43,000 submissions. An Administrative Law Judge hearing was scheduled for December 2024 but postponed to March 2025 due to procedural challenges from opponents including Smart Approaches to Marijuana. The formal rescheduling process remained incomplete when Biden left office in January 2025.

Trump's First Term and 2024 Campaign Positions (2017-2024)

During his first term (2017-2021), President Trump took limited direct action on cannabis policy, deferring to Attorney General Sessions' hardline approach until Sessions' departure in November 2018. Trump stated in June 2018 that he would "probably" support the STATES Act, bipartisan legislation to protect state cannabis programs, but did not actively lobby for its passage. Trump's 2024 campaign included explicit cannabis reform language for the first time. In a September 2024 Truth Social post, Trump stated he supported rescheduling and allowing states to "make their own decisions" on legalization. Florida's Amendment 3 adult-use initiative, which appeared on the November 2024 ballot, received Trump's public endorsement, though the measure ultimately failed with 58.9% support, short of the 60% threshold required for constitutional amendments in Florida.

The June 2026 Executive Action

On June 24, 2026, President Trump signed an executive order titled "Modernizing Federal Cannabis Policy and Eliminating Regulatory Barriers to State-Legal Commerce." The order directed the DEA to complete cannabis rescheduling to Schedule III within 90 days, instructed the Treasury Department to issue guidance providing SAFE Banking protections, and established an interagency task force to develop recommendations for federal taxation and interstate commerce frameworks. The action came one week after a June 17, 2026 Oval Office meeting with cannabis industry executives, including executives from Curaleaf, Green Thumb Industries, and California-based Glass House Brands. According to attendees who spoke on background, Trump focused on tax revenue potential and job creation, noting that legal cannabis employed more Americans than coal mining.

Key Players

Drug Enforcement Administration

The DEA holds statutory authority under 21 U.S.C. § 811 to reschedule controlled substances, making Administrator Anne Milgram the critical implementation figure for Trump's directive. Milgram, a Biden appointee who remained in the role, has not publicly commented on the executive order. DEA career staff have historically opposed rescheduling, with the agency denying citizen petitions to reschedule cannabis in 2001, 2006, and 2016. The 90-day deadline in Trump's order compresses a process that typically takes 18-36 months, creating questions about procedural compliance with the Administrative Procedure Act.

Department of Health and Human Services

HHS completed the scientific and medical evaluation that underpinned the Biden-era rescheduling recommendation. The department's August 2023 report to DEA found that cannabis has "currently accepted medical use" based on FDA-approved drugs containing cannabis-derived compounds, including Epidiolex for seizure disorders. HHS Secretary Robert F. Kennedy Jr., appointed by Trump in January 2025, has expressed support for medical cannabis access but has not detailed positions on scheduling.

Treasury Department and FinCEN

The Financial Crimes Enforcement Network, a Treasury bureau, issued the 2014 FinCEN Guidance that established the current framework for banks serving cannabis businesses. That guidance requires financial institutions to file Suspicious Activity Reports on all cannabis-related accounts, creating compliance costs that have limited participation to approximately 800 banks and credit unions nationwide. Trump's executive order directs Treasury to issue new guidance within 60 days providing explicit safe harbor, effectively implementing core provisions of the SAFE Banking Act without congressional action.

Internal Revenue Service

IRS enforcement of Section 280E has generated billions in federal revenue while crippling cannabis business economics. The agency has prevailed in Tax Court cases including Olive v. Commissioner (2015) and Alterman v. Commissioner (2018), establishing that 280E applies even to state-legal businesses. Rescheduling to Schedule III would automatically eliminate 280E applicability, as the statute applies only to Schedule I and II substances. The IRS has not issued guidance on transition procedures for businesses with pending audits or appeals.

Multi-State Operators

Publicly traded MSOs including Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, and Verano Holdings operate 1,500+ dispensaries across multiple states. These companies saw combined market capitalization increases exceeding $8 billion in the week following Trump's announcement. Curaleaf CEO Boris Jordan stated in a June 25 investor call that rescheduling would improve the company's EBITDA margin from 28% to an estimated 42-45%, generating approximately $180 million in annual tax savings.

California Cannabis Companies

Glass House Brands, the California cultivator referenced in triggering news reports, saw its market capitalization increase from approximately $340 million to over $1 billion between June 24-26, 2026. The company operates 5.5 million square feet of greenhouse cultivation in Carpinteria and Camarillo, producing approximately 150,000 pounds of flower annually. CEO Kyle Kazan attributed the valuation surge to anticipated interstate commerce opportunities and institutional investment access.

Opposition Groups

Smart Approaches to Marijuana, led by former Representative Patrick Kennedy, filed comments opposing the Biden-era NPRM and has indicated it will challenge Trump's executive action as procedurally deficient. The group argues that rescheduling requires completion of the formal APA rulemaking process, including ALJ hearings and response to public comments. SAM has retained former Solicitor General Paul Clement to evaluate litigation options.

Legal and Regulatory Framework

Trump's cannabis policy operates within a complex statutory architecture spanning the Controlled Substances Act, tax code, banking law, and administrative procedure requirements. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes the Attorney General's authority to reschedule substances through a process defined in 21 U.S.C. § 811. That statute requires the Attorney General to "request from the Secretary a scientific and medical evaluation, and his recommendations, as to whether such drug or other substance should be so controlled or removed as a controlled substance." The HHS Secretary's evaluation must consider eight factors, including the substance's actual or relative potential for abuse, scientific evidence of pharmacological effect, and risk to public health. The DEA has interpreted § 811 to require notice-and-comment rulemaking under the Administrative Procedure Act, 5 U.S.C. § 553. This process includes publication of an NPRM in the Federal Register, a comment period of at least 30 days, and consideration of comments before issuing a final rule. Parties may request a hearing before an ALJ, as occurred in the Biden-era rescheduling process. Trump's executive order attempts to compress this timeline to 90 days, raising questions about procedural validity. Administrative law experts including Professor Nicholas Bagley of the University of Michigan have noted that courts could vacate a rescheduling rule that fails to adequately respond to substantive comments or provide sufficient time for hearing requests. Internal Revenue Code Section 280E, enacted in 1982, provides that "no deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." The statute was enacted in response to Jeffrey Edmondson v. Commissioner, a 1981 Tax Court case allowing a cocaine trafficker to deduct business expenses. Because 280E references "schedule I and II," rescheduling cannabis to Schedule III would automatically eliminate the statute's application to cannabis businesses. The change would allow normal business deductions for rent, payroll, marketing, and other operating expenses. The Joint Committee on Taxation has not published revenue estimates for this change, but industry analysts project federal tax revenue would decline by $1-2 billion annually while cannabis business tax payments would increase due to improved profitability and expansion. The Bank Secrecy Act, 31 U.S.C. § 5311 et seq., requires financial institutions to report suspicious transactions and maintain anti-money laundering programs. The 2014 FinCEN Guidance established that cannabis transactions are inherently "suspicious" under federal law, requiring Suspicious Activity Reports. Banks must file "Cannabis Limited" SARs for customers engaged in state-legal cannabis business, "Cannabis Priority" SARs for activity implicating Cole Memo enforcement priorities, and "Cannabis Termination" SARs when closing accounts. This reporting regime creates compliance costs estimated at $15,000-$30,000 per account annually, limiting bank participation. The SAFE Banking Act, which has passed the House seven times since 2019 but never cleared the Senate, would provide that proceeds from state-legal cannabis business are not considered proceeds of unlawful activity under federal money laundering statutes. Trump's executive order directs Treasury to issue guidance achieving the same result through administrative action, though legal scholars debate whether such guidance can override statutory prohibitions.

State-by-State Breakdown

Twenty-four states, two territories, and the District of Columbia have legalized adult-use cannabis, while 38 states permit medical use, creating a patchwork that Trump's federal policy will affect differently based on local regulatory maturity.

California

California operates the nation's largest cannabis market, with $5.3 billion in legal sales in 2025. The state's regulatory framework, established by the Medicinal and Adult-Use Cannabis Regulation and Safety Act, includes cultivation licensing through the Department of Cannabis Control, testing requirements for pesticides and potency, and local control provisions that have resulted in 70% of jurisdictions prohibiting commercial cannabis activity. Adult possession limits are 28.5 grams of flower and 8 grams of concentrate. Trump's policy is expected to particularly benefit California cultivators facing interstate commerce opportunities, as the state's outdoor and greenhouse production costs are 40-60% below indoor cultivation in other states.

New York

New York legalized adult use through the Marijuana Regulation and Taxation Act on March 31, 2021, but licensed dispensary sales did not begin until December 29, 2022. The state's social equity licensing program has faced implementation challenges, with only 147 dispensaries open as of June 2026 compared to projections of 400+. Possession limits are three ounces of flower and 24 grams of concentrate. The state's high tax burden—13% retail excise tax plus 9% state sales tax plus local sales tax—has sustained a large illicit market. Rescheduling could enable New York operators to achieve profitability and expand, though the state's limited license count may constrain growth compared to open-license states.

Florida

Florida operates a medical-only program with approximately 890,000 registered patients, the second-largest medical program nationally. The state's vertical integration requirement limits licenses to companies operating cultivation, processing, and retail, creating a market dominated by Trulieve (53% market share). Adult-use legalization failed in November 2024 with 58.9% support, short of the 60% constitutional amendment threshold. Medical patients may possess up to 2.5 ounces in smokable form per 35-day period. Trump's policy will benefit Florida's vertically integrated operators through 280E relief, but the state's lack of adult-use sales limits growth potential compared to recreational markets.

Ohio

Ohio voters approved adult-use legalization through Issue 2 on November 7, 2023, with 57% support. Sales began August 6, 2024. The state's Division of Cannabis Control licenses cultivation, processing, and retail separately, with 350 dispensary licenses available. Possession limits are 2.5 ounces of flower. Ohio's market generated $428 million in sales during its first ten months, exceeding projections. The state's central location and population of 11.8 million position it as a potential interstate commerce hub if federal policy enables cross-state transactions.

Texas

Texas maintains one of the nation's most restrictive medical programs, limited to patients with epilepsy, seizure disorders, multiple sclerosis, spasticity, ALS, autism, terminal cancer, and incurable neurodegenerative disease. THC content is capped at 1% by weight. The Compassionate Use Program serves approximately 50,000 registered patients through three licensed operators. Possession of any amount of cannabis outside the medical program remains a criminal offense. Trump's federal policy is unlikely to affect Texas significantly absent state legislative action to expand the program or legalize adult use.

Illinois

Illinois legalized adult use through the Cannabis Regulation and Tax Act, effective January 1, 2020. The state's social equity licensing program has faced legal challenges, with a lottery system for dispensary licenses invalidated by courts and replaced with a scoring system. As of June 2026, Illinois has 110 dispensaries operating, serving a market that generated $1.76 billion in 2025 sales. Possession limits are 30 grams of flower for residents, 15 grams for non-residents. The state's 41% effective tax rate (including 7-25% cannabis tax based on THC content, 6.25% state sales tax, and local taxes) is the nation's highest, creating opportunities for tax-advantaged expansion if 280E relief improves operator economics.

Michigan

Michigan's adult-use market, launched November 1, 2019, has become the nation's third-largest with $3.1 billion in 2025 sales. The state's regulatory approach includes open licensing with no caps, local control allowing municipalities to opt in or out, and a 10% excise tax plus 6% sales tax. Possession limits are 2.5 ounces in public, 10 ounces at home. Michigan's wholesale prices have declined to $800-1,200 per pound for outdoor flower, among the nation's lowest, creating a competitive environment where 280E relief could enable consolidation and professionalization.

Massachusetts

Massachusetts legalized adult use through a November 2016 ballot initiative, with sales beginning November 20, 2018. The state's Cannabis Control Commission licenses cultivation, manufacturing, and retail separately, with 403 retail licenses issued as of June 2026. Possession limits are one ounce in public, 10 ounces at home. The state's market generated $2.2 billion in 2025 sales. Massachusetts operators face high real estate costs and local tax burdens—communities may impose up to 3% local sales tax on top of the 10.75% state excise tax and 6.25% sales tax—making 280E relief particularly valuable.

Market and Business Implications

Trump's cannabis policy is projected to unlock $15-20 billion in institutional capital, enable major exchange listings, and trigger industry consolidation as 280E relief separates profitable operators from marginal players. Multi-state operators stand to see immediate EBITDA margin expansion of 10-20 percentage points as 280E elimination allows normal business expense deductions. Curaleaf's investor presentation projects the company's adjusted EBITDA would increase from $465 million (2025) to $645-680 million on similar revenue, a 39-46% improvement. Green Thumb Industries estimates 280E relief would generate $140-160 million in annual tax savings, improving EBITDA margin from 31% to 42-44%. These improved economics will enable MSOs to service conventional debt, refinancing high-cost cannabis-specific loans carrying 12-18% interest rates with traditional bank debt at 6-8%. Analysts at Cowen estimate the cannabis industry carries $4.3 billion in debt at an average rate of 14.2%; refinancing could save $260-340 million annually in interest expense across the sector. Capital markets access represents a step-change opportunity. Cannabis companies currently trade on the Canadian Securities Exchange or over-the-counter markets in the U.S., limiting institutional ownership. Nasdaq and NYSE listing standards prohibit companies violating federal law. Rescheduling to Schedule III would remove this barrier, enabling uplisting to major exchanges. Companies meeting exchange financial requirements—including Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, and Verano—could list within 6-12 months of rescheduling finalization. Major exchange listings would open investment from index funds, which hold $11 trillion in assets and are generally prohibited from holding OTC securities. Mutual funds and pension funds, which manage $30 trillion combined, face similar restrictions. Industry analysts project that institutional ownership could reach 30-40% of cannabis company float within 24 months of uplisting, compared to less than 5% currently. Interstate commerce remains uncertain but represents the largest long-term opportunity. The Controlled Substances Act prohibits interstate trafficking in scheduled substances, but Schedule III substances may be transported across state lines with DEA registration and compliance with manufacturing and distribution regulations. If the Trump administration's interagency task force recommends an interstate commerce framework, low-cost producers in California, Michigan, and Oklahoma could ship to high-cost markets in New York, Illinois, and Massachusetts, potentially reducing retail prices by 20-35%. Wholesale pricing would face immediate pressure in an interstate environment. California greenhouse flower currently wholesales at $400-700 per pound; New York indoor flower wholesales at $2,000-2,800 per pound. Interstate commerce would compress this spread, benefiting consumers and retailers while challenging high-cost cultivators. Analysts project 30-40% of current cultivation capacity could become economically unviable within 18-24 months of interstate commerce implementation. Consolidation will accelerate as improved access to capital enables acquisitions. The cannabis industry remains highly fragmented, with the top five MSOs controlling approximately 18% of the legal market. By comparison, the top five alcohol distributors control 85% of that market, and the top five pharmaceutical wholesalers control 90% of drug distribution. Industry observers project the top 10 cannabis companies could control 40-50% of the market within five years if capital access and interstate commerce enable roll-up strategies. Ancillary businesses including testing laboratories, packaging suppliers, and software providers face mixed implications. Testing labs could see volume increases as federal rescheduling enables FDA oversight and potential pharmaceutical development, but interstate commerce could reduce the number of required tests as products cross state lines. Packaging suppliers may benefit from increased volume but face margin pressure as scale economies emerge. Software providers offering seed-to-sale tracking and compliance tools could see enterprise value increases as institutional buyers enter the sector.

What Experts Say

Industry analysts, legal scholars, and policy advocates have offered divergent assessments of Trump's cannabis policy, with supporters emphasizing economic benefits and critics questioning procedural legitimacy and public health implications. According to Aaron Smith, co-founder and chief executive of the National Cannabis Industry Association, the executive action represents "the most significant federal cannabis policy development since the Controlled Substances Act was enacted." Smith noted in a June 25 statement that NCIA member companies have paid an estimated $2.8 billion in excess federal taxes due to 280E over the past five years, capital that could have supported expansion and job creation. Marijuana Policy Project executive director Steve Hawkins characterized the policy as "long overdue recognition that federal cannabis prohibition has failed." Hawkins stated that the Trump administration's approach, while not full legalization, creates a framework that "respects state sovereignty while eliminating the most punitive federal barriers to legitimate business operations." Professor Sam Kamin of the University of Denver Sturm College of Law, an expert on cannabis federalism, expressed concerns about the executive order's procedural shortcuts. According to Kamin, the 90-day deadline for DEA rescheduling "compresses a process that typically takes years and raises serious Administrative Procedure Act questions." Kamin noted that courts could vacate a rescheduling rule that fails to adequately address public comments or provide sufficient opportunity for hearing requests. Kevin Sabet, president of Smart Approaches to Marijuana and former senior drug policy advisor in the Obama administration, characterized Trump's action as "reckless policy-making that prioritizes industry profits over public health." According to Sabet, rescheduling to Schedule III would "maintain cannabis as a controlled substance while eliminating the tax and banking barriers that have appropriately limited industry growth." SAM has indicated it will pursue litigation challenging the rescheduling process. Beau Kilmer, co-director of the RAND Drug Policy Research Center, noted that rescheduling creates "significant open questions about FDA jurisdiction and pharmaceutical regulation." According to Kilmer, Schedule III substances are subject to FDA oversight for medical use, potentially requiring cannabis products to undergo the drug approval process. This could create a two-tier market with FDA-approved pharmaceutical cannabis products and state-regulated adult-use products operating under different frameworks. Emily Pera, a former Colorado assistant attorney general who helped develop that state's regulatory framework, stated that the policy "will test state regulatory capacity in unprecedented ways." According to Pera, states will need to adapt licensing, testing, and enforcement systems to account for federal rescheduling, potential interstate commerce, and institutional capital entry. States with mature regulatory programs including Colorado, Washington, and Oregon are best positioned to manage the transition, while newer programs may face challenges. Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws, emphasized that rescheduling "is not legalization and leaves millions of Americans at risk of arrest for simple possession." According to Fox, approximately 350,000 Americans are arrested annually for cannabis possession offenses, primarily in states without legalization. Fox stated that NORML will continue advocating for descheduling—complete removal from the Controlled Substances Act—as the appropriate policy endpoint.

What's Next

The next 180 days will determine whether Trump's cannabis policy survives legal challenges, how quickly DEA completes rescheduling, and whether Treasury's banking guidance provides the safe harbor industry seeks. The immediate timeline includes several critical milestones. DEA faces a 90-day deadline (September 22, 2026) to complete rescheduling under Trump's executive order. The agency must publish a final rule in the Federal Register, respond to comments from the Biden-era NPRM, and address any hearing requests. Legal experts project the agency will struggle to meet this deadline while satisfying APA procedural requirements, potentially extending the process to December 2026 or early 2027. Treasury's Financial Crimes Enforcement Network has a 60-day deadline (August 23, 2026) to issue banking guidance. The guidance must address whether cannabis proceeds are considered proceeds of unlawful activity under 18 U.S.C. § 1956 and 1957, whether banks must file Suspicious Activity Reports on cannabis accounts, and what due diligence standards apply. Banking industry groups including the American Bankers Association have requested clarity on federal deposit insurance eligibility and examination procedures for cannabis-banking institutions. Litigation is virtually certain. Smart Approaches to Marijuana has retained counsel and indicated it will challenge the rescheduling process as procedurally deficient. Potential claims include failure to provide adequate time for public comment, inadequate response to substantive comments, and arbitrary and capricious decision-making under the APA. Courts could issue preliminary injunctions blocking rescheduling implementation pending resolution of these claims, a process that could take 18-36 months. Congressional response remains uncertain. Senate Majority Leader and House Speaker have not commented on Trump's executive action. Some Republican members, including Senator Tom Cotton of Arkansas, have expressed opposition to federal cannabis policy liberalization. Democratic members including Senate Majority Leader Chuck Schumer have called for full descheduling rather than rescheduling, arguing that Schedule III maintains cannabis as a controlled substance subject to federal enforcement. The appropriations process could affect implementation. Congress could include riders in fiscal year 2027 appropriations bills prohibiting agencies from using funds to implement the executive order, similar to riders that have protected state medical cannabis programs since 2014. Alternatively, Congress could pass legislation codifying or expanding the policy, though the divided political landscape makes major cannabis legislation unlikely in the near term. State legislative sessions in early 2027 will address implementation questions. States will need to determine whether to modify licensing caps, adjust tax rates to remain competitive in an interstate environment, and update testing and labeling requirements to align with potential federal standards. California, New York, and Illinois have indicated they will convene stakeholder working groups to develop recommendations for legislative action. FDA's role will become clearer in late 2026 and 2027. If cannabis is rescheduled to Schedule III, the agency gains jurisdiction over medical cannabis products. FDA could require pharmaceutical approval for products making therapeutic claims, potentially creating a two-tier market with prescription cannabis medications and adult-use products. The agency has not indicated how it would approach this regulatory challenge, but officials have noted that the approval process typically takes 8-12 years and costs $1-2 billion per drug. International treaty obligations present additional complexity. The United States is party to the 1961 Single Convention on Narcotic Drugs, which requires signatories to limit cannabis to medical and scientific use. Rescheduling to Schedule III while maintaining adult-use state programs could place the U.S. in violation of treaty obligations, though the practical consequences are unclear. Canada and Uruguay have legalized adult use while remaining Single Convention parties, and no enforcement mechanism has been invoked. Market evolution will accelerate regardless of policy uncertainty. Institutional investors are already positioning for rescheduling, with private equity firms including Poseidon Asset Management, Tuatara Capital, and Merida Capital Partners raising new funds totaling over $1 billion in the first half of 2026. These funds are targeting acquisitions of cultivation facilities, brands, and retail chains in anticipation of consolidation opportunities.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• Internal Revenue Code Section 280E - https://www.law.cornell.edu/uscode/text/26/280E
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (May 21, 2024) - https://www.federalregister.gov/documents/2024/05/21/2024-11137/sched